STI571: a gene product-targeted therapy for leukemia. Review uri icon

Overview

abstract

  • Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.

publication date

  • May 1, 2001

Research

keywords

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Genetic Therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Piperazines
  • Protein-Tyrosine Kinases
  • Pyrimidines

Identity

Scopus Document Identifier

  • 0035344667

Digital Object Identifier (DOI)

  • 10.1007/s11912-001-0054-z

PubMed ID

  • 11296132

Additional Document Info

volume

  • 3

issue

  • 3